Aurogra

Aurogra is a pharmaceutical formulation containing Sildenafil Citrate, a well-established phosphodiesterase type 5 (PDE5) inhibitor approved for the management of erectile dysfunction (ED). It functions by enhancing blood flow to the cavernosal bodies of the penis upon sexual stimulation, facilitating the achievement and maintenance of an erection sufficient for satisfactory sexual activity. This medication is recognized for its high bioavailability and rapid onset of action, typically within 30 to 60 minutes post-administration. It is intended for use by adult males and requires a proper clinical diagnosis prior to prescription. Aurogra represents a reliable therapeutic option within the class of ED treatments, backed by extensive clinical research and a well-understood mechanism of action.

Features

• Active Pharmaceutical Ingredient: Sildenafil Citrate 100mg
• Pharmacological Class: Phosphodiesterase Type 5 (PDE5) Inhibitor
• Standard Dosage Form: Film-coated tablet for oral administration
• Onset of Action: Typically 30–60 minutes post-dose
• Duration of Effect: Up to 4–6 hours
• Prescription Status: Rx-only medication requiring medical consultation
• Manufacturing Standards: Produced in facilities compliant with cGMP (current Good Manufacturing Practices)

Benefits

• Clinically proven efficacy in achieving and sustaining erections adequate for sexual intercourse.
• Rapid onset allows for spontaneity, with effects noticeable within approximately 30 to 60 minutes.
• High success rates across various etiologies of erectile dysfunction, including organic, psychogenic, and mixed causes.
• Well-characterized safety profile supported by decades of post-marketing surveillance and clinical use.
• Improves confidence and sexual satisfaction, contributing to overall quality of life and relationship well-being.
• Cost-effective alternative within the sildenafil-based treatment options.

Common use

Aurogra is primarily indicated for the treatment of erectile dysfunction in adult males. It is used on an as-needed basis to facilitate erectile function. The medication is not an aphrodisiac and requires sexual stimulation to be effective. It is commonly prescribed for individuals experiencing difficulties in achieving or maintaining an erection sufficient for satisfactory sexual performance due to various underlying physiological or psychological factors.

Dosage and direction

The recommended starting dose for most patients is 50mg taken approximately one hour before anticipated sexual activity. Based on efficacy and tolerability, the dose may be increased to a maximum of 100mg or decreased to 25mg. The tablet should be swallowed whole with a glass of water; it may be taken with or without food, though a high-fat meal may delay onset of action. Aurogra should not be taken more than once per 24-hour period. Dosage adjustments are necessary for patients with hepatic impairment, severe renal impairment, or those taking certain concomitant medications—consult a healthcare provider for personalized dosing.

Precautions

Prior to initiating treatment with Aurogra, a thorough medical evaluation should be conducted to diagnose erectile dysfunction and identify potential underlying health conditions. Use with caution in patients with anatomical deformation of the penis, conditions that may predispose to priapism, bleeding disorders, or active peptic ulceration. Cardiovascular status should be assessed, as sexual activity carries potential cardiac risk. Aurogra offers no protection against sexually transmitted diseases. Avoid consumption of grapefruit juice, as it may increase plasma concentrations of sildenafil. Alcohol intake should be moderated, as it can increase the risk of orthostatic hypotension.

Contraindications

Aurogra is contraindicated in patients with a known hypersensitivity to sildenafil or any component of the formulation. Concurrent use with organic nitrates or nitric oxide donors in any form is absolutely contraindicated due to the risk of profound hypotension. It is also contraindicated in patients using guanylate cyclase stimulators. Avoid use in men for whom sexual activity is inadvisable due to underlying cardiovascular conditions. Not indicated for use in women, children, or neonates.

Possible side effect

The most commonly reported adverse reactions are headache, flushing, dyspepsia, nasal congestion, and dizziness. Visual disturbances such as altered color vision, blurred vision, or photophobia may occur. Less frequently, patients may experience back pain, myalgia, or nausea. Priapism is a rare but serious adverse event requiring immediate medical attention to avoid permanent damage. Sudden hearing loss or non-arteritic anterior ischemic optic neuropathy have been reported in temporal association with PDE5 inhibitor use. Most side effects are mild to moderate and transient in nature.

Drug interaction

Concomitant use with nitrates is contraindicated. Alpha-blockers may potentiate the blood pressure-lowering effects. CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, erythromycin) can increase sildenafil concentrations—dose adjustment is necessary. Inducers of CYP3A4 may decrease plasma levels. Use with other antihypertensives may add to the hypotensive effect. Aurogra may potentiate the anticoagulant effect of warfarin. Always inform your healthcare provider of all medications, including over-the-counter drugs and herbal supplements.

Missed dose

Aurogra is not intended for chronic daily dosing; it is taken on an as-needed basis. Therefore, the concept of a “missed dose” does not apply. Do not take an extra dose to make up for a missed opportunity. Adhere strictly to the maximum frequency of one dose per 24 hours.

Overdose

In cases of overdose, the expected effects would be an exaggeration of the known dose-dependent adverse reactions, including severe hypotension, syncope, and prolonged erection. Standard supportive measures should be employed, including keeping the patient in a supine position with the legs elevated to manage hypotension. Priapism lasting more than 4 hours requires urgent urological intervention to prevent corporal tissue damage and permanent erectile dysfunction. Dialysis is not expected to accelerate clearance, as sildenafil is highly protein-bound.

Storage

Store Aurogra tablets at room temperature, between 15–30°C (59–86°F), in their original packaging to protect from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly discard any unused or expired medication as per local guidelines—do not flush down the toilet or drain unless instructed.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Aurogra is a prescription medication and must be used under the supervision of a qualified healthcare professional. Only a licensed physician can determine if this treatment is appropriate based on individual health status, medical history, and risk factors. Never self-diagnose or self-prescribe for erectile dysfunction.

Reviews

“After a thorough cardiovascular workup, my physician prescribed Aurogra. The effect was consistent and reliable, with onset around 40 minutes. Side effects were minimal—mild flushing that subsided quickly. It has significantly improved my confidence and sexual relationship.” – Verified Patient, 54

“In my clinical practice, I find Aurogra to be a cost-effective option for many patients with erectile dysfunction. Its pharmacokinetic profile is well-suited for on-demand use, and patients report high satisfaction when appropriate candidate selection is performed.” – Urologist, 15 years experience

“I was initially apprehensive, but the efficacy was evident. It worked as described, though I did experience some nasal congestion. Taking it on an empty stomach seemed to speed up the onset. Important to follow the dosing instructions precisely.” – Verified Patient, 48